Moreover, given that the intratumoral heterogeneity and underpinning mechanisms of plasticity remain poorly defined, it will be important to determine how easily mesenchymal cells can adapt and resist TAK1 inhibition, and if a pro-inflammatory TME or even cancer immunotherapy can potentiate treatment efficacy. The gene discussed is MAP3K7; the disease is cancer.